#United States #New York #dermatology #Mount Sinai #Sun Pharma

Sun Pharma Launches an Endowed Professorship

Sun Pharmaceutical Industries Limited has made a significant stride in advancing dermatologic care by establishing the Sun Professorship in Dermatology at the Icahn School of Medicine at Mount Sinai. This initiative is supported by a generous endowment of $2.5 million, designed to ensure the ongoing leadership in dermatology education, research, and mentorship.

Mark G. Lebwohl, M.D. has been appointed as the initial holder of this esteemed position. The announcement was made during an official ceremony held at the Hatch Auditorium at The Mount Sinai Hospital in New York. With this professorship, Sun Pharma aims to not only enhance academic leadership but to translate the latest research into improved patient care while also cultivating future leaders in dermatology.

Dr. Lebwohl, who is currently the Dean for Clinical Therapeutics at Mount Sinai and the Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology, is a prominent figure in psoriasis treatment and research. His work has significantly advanced the understanding of inflammatory skin diseases. He has played a critical role in establishing standards of care that have benefitted countless patients worldwide. Beyond clinical practice, Dr. Lebwohl has demonstrated a commitment to mentoring the next generation of dermatologists, thus leaving a lasting mark on the field.

Ahmad Naim, M.D., Senior Vice President and Chief Medical Officer for North America at Sun Pharma, emphasized the company's dedication to fostering the academic foundations necessary for dermatology's progression. He remarked, "At Sun Pharma, we believe meaningful progress in dermatology care requires supporting the people and institutions advancing the field today and in the future. This professorship reflects our long-term commitment to this cause."

Emma Guttman, M.D., Ph.D., who is the Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology, echoed the sentiments expressed by Dr. Naim. She highlighted that both Mount Sinai and Sun Pharma have a shared mission of improving care for patients suffering from severe skin conditions. Dr. Guttman stated, "This professorship reflects a shared belief that investing in scientific excellence and academic leadership ultimately leads to better outcomes for patients around the world."

The dermatology field has witnessed remarkable advancements over the years, and continued progress, as noted by Guttman, necessitates the support for emerging clinicians and researchers. Dr. Lebwohl's influence extends far beyond his research contributions; he has been instrumental in guiding countless physicians throughout his career, ensuring a dynamic future for dermatology.

"I am deeply honored to be named the inaugural holder of the Sun Professorship in Dermatology," said Dr. Lebwohl. He recognized the potential of the professorship in providing opportunities to address critical questions in dermatology, nurture promising researchers, and convert scientific advancements into improved patient care.

Sun Pharma is noted for its commitment to enhancing dermatologic care through scientific development and community partnerships. As the second-largest pharmaceutical dermatology company in the U.S. by prescription volume, their endeavors extend globally, ensuring that individuals in over 100 countries receive high-quality medications.

This development is a landmark moment in dermatology as it reinforces the importance of academic leadership in shaping the future of care for patients. With the Sun Professorship, Dr. Lebwohl, along with the support of Sun Pharma and Mount Sinai, is set to cultivate research initiatives and educational programs that will shape best practices in dermatology for generations to come.

Sun Pharmaceutical Industries Limited continues to be a front-runner in the pharmaceutical sector, not just in the field of dermatology but also in a wide array of medical conditions. The establishment of this professorship marks a significant commitment to the future of dermatologic care, demonstrating how collaborations between academic institutions and pharmaceutical companies can ultimately lead to better health outcomes for patients around the world.